venBio Partners LLC Makes New Investment in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

venBio Partners LLC acquired a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,102,190 shares of the company's stock, valued at approximately $4,545,000. Lyell Immunopharma comprises about 2.7% of venBio Partners LLC's investment portfolio, making the stock its 7th biggest position. venBio Partners LLC owned approximately 2.43% of Lyell Immunopharma as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Decheng Capital LLC bought a new position in shares of Lyell Immunopharma in the 4th quarter worth about $7,622,000. Foresite Capital Management V LLC acquired a new position in shares of Lyell Immunopharma during the 4th quarter valued at $5,205,000. Renaissance Technologies LLC boosted its stake in Lyell Immunopharma by 716.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock worth $1,032,000 after acquiring an additional 1,414,746 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Lyell Immunopharma in the fourth quarter worth $887,000. Finally, Almitas Capital LLC acquired a new stake in Lyell Immunopharma in the fourth quarter worth $672,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Lyell Immunopharma

In other Lyell Immunopharma news, CEO Lynn Seely acquired 175,000 shares of the company's stock in a transaction on Friday, March 14th. The shares were acquired at an average cost of $0.61 per share, with a total value of $106,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 712,500 shares in the company, valued at $434,625. This trade represents a 32.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Sumant Ramachandra purchased 200,000 shares of the business's stock in a transaction dated Friday, March 21st. The stock was bought at an average cost of $0.58 per share, with a total value of $116,000.00. Following the completion of the acquisition, the director now directly owns 200,000 shares of the company's stock, valued at approximately $116,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 768,640 shares of company stock worth $449,508. 25.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "neutral" rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

Lyell Immunopharma Stock Performance

Shares of LYEL opened at $0.41 on Tuesday. The firm has a market capitalization of $122.00 million, a P/E ratio of -0.52 and a beta of -0.25. Lyell Immunopharma, Inc. has a 52 week low of $0.39 and a 52 week high of $2.85. The stock has a 50 day moving average price of $0.47 and a two-hundred day moving average price of $0.66.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The firm had revenue of $0.01 million during the quarter. On average, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

Want to see what other hedge funds are holding LYEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.